1. Scrip
  2. >>Therapy Areas
  3. >>Sensory

Iveric's Zimura Succeeds In Dry AMD Study

Stock Sees Three-Day Gain Of 283%

 
• By Kevin Grogan

The New York-headquartered  firm, which recently decided to focus on gene therapy, has to decide whether to partner Zimura or go it alone.

Eyes
The eyes have it for Iveric • Source: Shutterstock

Shares in Iveric Bio are continuing to soar after the small US biotech said its lead asset Zimura slowed eyesight deterioration in patients with dry age-related macular degeneration (AMD).

Top-line data from a Phase IIb trial of Zimura (avacincaptad pegol) showed that the complement C5 inhibitor reduced the rate of geographic atrophy (GA) in people with dry AMD compared to a sham control group. Specifically, Iveric, which was formerly known as Ophthotech Corp

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Sensory

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.